Therapies

What Is Briumvi® Infusion Therapy?

A B-cell therapy approved for relapsing multiple sclerosis (RMS)
, What Is Briumvi Infusion Therapy?, Healix Infusion Care
, What Is Briumvi Infusion Therapy?, Healix Infusion Care
, What Is Briumvi Infusion Therapy?, Healix Infusion Care

Briumvi® Infusion

Briumvi® (ublituximab-xiiy) offers a targeted approach for patients managing relapsing forms of multiple sclerosis, delivering a B-cell therapy designed to slow disease progression. Combined with regular monitoring by a specialized healthcare team, Briumvi infusion therapy aims to help reduce the frequency of MS flares while minimizing potential side effects.

What Is Briumvi Infusion Therapy Used For?

Briumvi infusion therapy helps treat certain forms of multiple sclerosis. The intravenous infusion works by targeting the CD20 protein on specific B-cells, which are white blood cells involved in the immune response. When Briumvi attaches to these cells, they are depleted. This reduces harmful immune activity in the central nervous system and helps lower relapse rates and disease progression in MS.

Which Forms of MS Does Briumvi Treat?

Briumvi was approved by the FDA in 2022 for the treatment of the following relapsing forms of MS in adults:

  • Clinically isolated syndrome
  • Relapsing-remitting multiple sclerosis
  • Active secondary progressive multiple sclerosis

Briumvi infusion therapy is not indicated for primary progressive MS or nonactive SPMS.

What Are the Possible Side Effects of Briumvi?

Patients taking Briumvi may experience a reaction to the infusion, usually within the first 24 hours. These include flu-like symptoms, rapid heartbeat, itchiness, dizziness, swelling of the tongue or throat, and difficulty breathing.

If any of these symptoms arise during your infusion, notify your treatment team right away. The infusion may need to be slowed or temporarily stopped to manage the patient’s comfort and safety. If you have any continued symptoms after the infusion, please inform your treatment team and your referring provider.

Common Briumvi side effects include:

  • Upper or lower respiratory infections
  • Herpes infections
  • Arm and leg pain
  • Insomnia
  • Fatigue

Additional rare side effects are also possible:

  • Severe allergic reactions
  • Progressive multifocal leukoencephalopathy
  • Hepatitis B virus reactivation
  • Low immunoglobulin levels
  • Severe infusion reactions
  • Serious respiratory infections

Patients should inform their physician about all medical conditions before beginning Briumvi therapy, especially if they have current or past infections (including hepatitis B) or if they take medications that affect the immune system.

Physicians also need to know if patients are pregnant, plan to become pregnant, or are breastfeeding so the care team can provide appropriate guidance regarding Briumvi treatment.

, What Is Briumvi Infusion Therapy?, Healix Infusion Care
, What Is Briumvi Infusion Therapy?, Healix Infusion Care
, What Is Briumvi Infusion Therapy?, Healix Infusion Care
, What Is Briumvi Infusion Therapy?, Healix Infusion Care
, What Is Briumvi Infusion Therapy?, Healix Infusion Care

How Much Does Briumvi Cost?

Where treatment is administered can significantly influence overall expenses. For example, according to the AHIP, outpatient infusion centers typically cost an average of $7,000 less than hospitals, which apply additional facility fees and higher service charges.

Briumvi also offers a copay assistance program for eligible patients that can reduce yearly costs.

Briumvi Prescribing Information Highlights

These prescribing information highlights do not include all the information required to ensure Briumvi is used safely and effectively. Healthcare providers should review the full Briumvi prescribing information for complete details on usage, warnings, and precautions.

Treatment Preparation 

Before administering the first dose of Briumvi, conduct the following assessments:

  • HBV Screening: Briumvi is contraindicated for patients with active hepatitis B
  • Serum Immunoglobulins: Consult an immunologist for recommendations for patients with low Igs
  • Vaccinations: Live-attenuated or live vaccines should be administered at least four weeks prior to infusion therapy; two weeks for non-live vaccines

Briumvi infusions may raise the risk of serious infections or potentially cause fetal harm. Therefore, healthcare providers should evaluate patients for active infections and check for pregnancy before each infusion.

Pre-Infusion Medications

To reduce the risk and severity of infusion-related reactions, pre-medicate with the following before each Briumvi infusion:

  • Methylprednisolone (100 mg) intravenously (or an equivalent corticosteroid) approximately 30 minutes prior
  • Antihistamine (e.g., diphenhydramine) orally or intravenously approximately 30 to 60 minutes prior
  • Antipyretic (e.g., acetaminophen) prior to each infusion

Healthcare providers may adjust the choice and dosage of antihistamines and antipyretics based on individual patient factors and clinical judgment.

Treatment Time and Dosage

The first two intravenous infusions should be administered on day 1 and day 15, with maintenance infusions every 24 weeks:

  • First infusion is 150 mg (6 mL) over 4 hours:
    • 10 mL/hr for the first 30 minutes
    • 20 mL/hr for the next 30 minutes
    • 35 mL/hr for the next hour
    • 100 mL/hr for the remaining 2 hours
  • Second and subsequent infusions are 450 mg (18 mL) over 1 hour:
    • 100 mL/hr for the first 30 minutes
    • 400 mL/hr for the remaining 30 minutes

Choose Healix for Your Briumvi Infusion Therapy

Patients who require Briumvi therapy or any other infusion treatment for a chronic condition can rely on the dedicated services provided by Healix Infusion Care. Our team delivers effective, patient-focused support for a range of treatment needs. Learn more about the conditions we treat and how Healix can help.

, What Is Briumvi Infusion Therapy?, Healix Infusion Care
Explore More Therapies

No Results Found

The posts you requested could not be found. Try changing your module settings or create some new posts.